# Revvity

the LabChip GX platform miniaturizes capillary electrophoresis onto a microfluidic chip for rapid nucleic-acid fragment sizing, an application vendors are actively optimizing for plasmid DNA and mRNA/gene-therapy QC.


Source: https://en.bioecon.ru/companies/revvity/
Updated: 2026-08-15

- Country: United States
- Ticker: NYSE:RVTY

## Verifiable facts

| Fact | Value | Source |
| --- | --- | --- |
| Headcount | approximately 11,000 employees worldwide (2025-12-28) | https://www.sec.gov/Archives/edgar/data/31791/000119312526107279/d29235dars.pdf, https://www.stocktitan.net/sec-filings/RVTY/10-k-revvity-inc-files-annual-report-9c2a994bbee8.html |
| Revenue | approximately $2.8 billion for 2024E (2024-12-31) [medium confidence] | https://s202.q4cdn.com/560601150/files/doc_presentation/2024/11/Revvity-Investor-Day-2024.pdf |
| Certification | Many large manufacturing sites are ISO 45001 and 14001 certified | https://www.sec.gov/Archives/edgar/data/31791/000119312526107279/d29235dars.pdf, https://www.stocktitan.net/sec-filings/RVTY/10-k-revvity-inc-files-annual-report-9c2a994bbee8.html |
| Regulatory approval | Instruments support FDA 21 CFR Part 11 compliance | https://www.revvity.com/category/microfluidic-nucleic-acid-analysis, https://www.revvity.com/category/microfluidic-protein-characterization |
| Production site | State-of-the-art manufacturing facilities for custom chip fabrication and microfluidics [medium confidence] | https://www.revvity.com/category/microfluidic-analysis |
| Capacity | AAV manufacturing capacity from 30mL research-scale to 10 L batches [medium confidence] | https://www.revvity.com/category/aav-services |

Independent sources: s202.q4cdn.com, sec.gov, stocktitan.net

## Technologies

- [Capillary electrophoresis for biopharma](https://en.bioecon.ru/technology/capillary-electrophoresis-biopharma/)
- [Plate readers for bioproduction](https://en.bioecon.ru/technology/plate-readers-bioproduction/)